logo
  • Über uns
    • Über uns
    • Führungsteam
    • Unsere Verantwortung
    • Kollaborationen
    • Unsere Standorte
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Analysten-Coverage
    • Hauptversammlung
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Oncology

Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors


by Sovereign

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer


by Sovereign

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer


by Sovereign

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors


by Sovereign

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy


by Sovereign

Immunological effects of a novel RNA-based adjuvant in liver cancer patients


by Sovereign

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study


by Sovereign

A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile


by Sovereign

mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer


by Sovereign

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors


by Sovereign

  • 1
  • 2